NCT03457896 2022-03-31Study of Neratinib +Trastuzumab or Neratinib + Cetuximab in Patients With KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer by HER2 StatusNSABP Foundation IncPhase 2 Unknown35 enrolled